NIH extends PPD HIV research support contract until 2024
Pharmaceutical Product Development, LLC (PPD) has secured a renewal of its contract with the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the fifth time.
The contracts range from five to seven years and involve monitoring for approximately 150 clinical studies per contract.
The original NIAID/DAIDS contract was awarded 27 years ago, and the latest renewal will extend the clinical trial services relationship until 2024.
Patti McNamara, vice president, government and public health services for PPD, told us the relationship has expanded since 1990.
“While the core services have remained the same, the underlying protocols have grown in number, size and complexity as the science has matured,” explained McNamara.
As part of the relationship, PPD predicts risks to clinical trial participant safety and data integrity based on measures of site performance and other known risk factors.
Additionally, she said the contract value has more than tripled for the current contract period versus the contract initially awarded in 1990. The CRO is also now monitoring projects at sites throughout the world.
“The extension covers site monitoring for HIV treatment and prevention clinical trials. Sites are located around the world with the highest number in the US and Africa,” said McNamara.
“Over the years, we have partnered with DAIDS to support this important organization’s global research efforts to advance the biological knowledge of HIV/AIDS and its related co-infections and co-morbidities, with the ultimate goal of creating an AIDS-free generation.”
